复发的TCF3-HLF阳性B细胞急性淋巴细胞白血病中的CD19嵌合抗原受体T细胞疗法 - Suppr

CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia.

作者信息

Yao Yao, Zhou Jin, Li Yanting, Shi Sensen, Yu Lei, Wu Depei, Wang Ying

机构信息

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

出版信息

Ann Hematol. 2024 Dec;103(12):6031-6033. doi: 10.1007/s00277-024-05945-z. Epub 2024 Aug 15.

DOI:10.1007/s00277-024-05945-z

PMID:39145779

Abstract

摘要

相似文献

CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia.

Ann Hematol. 2024 Dec;103(12):6031-6033. doi: 10.1007/s00277-024-05945-z. Epub 2024 Aug 15.

Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.

Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):386-392. doi: 10.1016/j.clml.2021.01.014. Epub 2021 Jan 28.

[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].

Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):495-501. doi: 10.3760/cma.j.issn.0253-2727.2020.06.011.

[Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].

Zhonghua Xue Ye Xue Za Zhi. 2021 May 14;42(5):383-389. doi: 10.3760/cma.j.issn.0253-2727.2021.05.006.

[In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].

Zhonghua Xue Ye Xue Za Zhi. 2021 Feb 14;42(2):140-145. doi: 10.3760/cma.j.issn.0253-2727.2021.02.009.

Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.

Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.

CD4CD25CD127 regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.

Int Immunopharmacol. 2021 Jul;96:107742. doi: 10.1016/j.intimp.2021.107742. Epub 2021 May 11.

NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia.

Epigenomics. 2018 Feb;10(2):133-147. doi: 10.2217/epi-2017-0080. Epub 2018 Jan 15.

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.

BMC Cancer. 2022 Apr 12;22(1):393. doi: 10.1186/s12885-022-09489-1.

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Blood Cancer J. 2023 Apr 24;13(1):60. doi: 10.1038/s41408-023-00819-5.

引用本文的文献

"A novel approach to understanding the role of TCF3 mutations in childhood B-cell precursor acute lymphoblastic leukemia".

Transl Oncol. 2025 Aug 13;61:102505. doi: 10.1016/j.tranon.2025.102505.

本文引用的文献

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Blood Cancer J. 2023 Apr 24;13(1):60. doi: 10.1038/s41408-023-00819-5.

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.

Blood. 2022 Apr 7;139(14):2173-2185. doi: 10.1182/blood.2021012727.

The advantage of chimeric antigen receptor T cell therapy in pediatric acute lymphoblastic leukemia with E2A-HLF fusion gene positivity: a case series.

Transl Pediatr. 2021 Mar;10(3):686-691. doi: 10.21037/tp-20-323.

Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.

Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):386-392. doi: 10.1016/j.clml.2021.01.014. Epub 2021 Jan 28.

Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor.

Blood. 2018 Nov 1;132(18):1899-1910. doi: 10.1182/blood-2017-12-815548. Epub 2018 Sep 12.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13.

Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.

Leukemia. 2012 Dec;26(12):2483-93. doi: 10.1038/leu.2012.139. Epub 2012 May 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献